Physician profile

Gerald Vocke

Metairie, LA

NPI 1871597633

$983.61

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$302.26

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $341.30 2021-2024 Nucala, Trelegy Ellipta
Optinose US, INC. $170.40 2019-2022
Regeneron Healthcare Solutions, INC. $108.80 2020-2023 Dupixent
Abbvie INC. $97.36 2021-2024
Alk-Abello, INC $80.18 2020-2022
Astrazeneca Pharmaceuticals LP $61.80 2021-2024 Airsupra
Hikma Pharmaceuticals USA $37.76 2023 Ryaltris
Genentech USA, INC. $30.32 2021-2022
Stryker Corporation $21.58 2022
Itamar Medical INC $18.83 2023 Watchpatone
Olympus America INC. $15.28 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Gerald Vocke

$983.61

in general payments reported 2019-2025

Years
2019-2024
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/176067/gerald-vocke

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.